|
Results 2008
The year 2008 for Octapharma was focused on consolidation and introduction of our own plasma production, with investments exceeding €110 M. Against this perspective, for the fourth consecutive year, Octapharma realised a record turnover and profitability. Our Net turnover increased by 17.8 % to €886 M in 2008, compared to €752 M in 2007.
In terms of gross profit, we experienced an increase from €339 M in 2007 to €367 M € in 2008. The gross margin decreased from 45 % to 41 % as a result of increased plasma costs brought about mainly by introduction of our own plasma production capacities (i.e. more than €50 M spent). This could not be fully offset by the better utilisation of our production.
Continuous cost awareness together with sustained efficiencies in our processes ensured that the operating costs remained at €117 M versus €104 M in 2007. This meant that Octapharma reached a satisfactory level in its operating income (earnings before interest and taxes) of €256 M (28.9 % margin), compared with € 237 M (31.6 % margin) in 2007.
Overall, the 2008 results of €231 M against €207 M in 2007 exceeded our budget and in line with the management expectations, especially when we factor in the considerable establishment costs related to Octapharma’s own plasma production in the USA, Czech Republic and Germany.
As regards liquidity, the continued positive results have ensured that there is a cash buffer above €260 M by year end 2008, strongly enhanced by an equity of €751 M or 73.3 % of the balance sum, guaranteeing the financial basis for the planned investments and continue our growth in the coming years.
Octapharma has benefited largely from the very positive developments in the market. However, Chairman Wolfgang Marguerre emphasised that Octapharma’s outstanding results in 2008 came into fruition primarily because of the good contribution and impressive performance of all employees.
Looking forward, the main outlook for Octapharma in the year 2009 will remain positive. The increase in turnover and net income is expected to be again above 20 % against the backdrop of increased competition and constraints in our production capacity.
 Annual Report 2002 (3.52 MB)
Annual Report 2003 (2.15 MB)
Annual Report 2004 (2.57) MB)
Annual Report 2005 (1.51 MB)
Annual Report 2006 (1.48 MB)
Annual Report 2007 (1.42 MB)
|
|
 |
|
|
